case_images: PMC5939903_01
case_images: Percentage changes in lumbar BMD (A) and total hip BMD (B) before, and at 6-8, 12, 18, and 24 months after denosumab therapy.. Note: Patient 2 was followed up for 18 months, not 24 months.. Abbreviations: BMD, bone mineral density; M, months.
case_images: tcrm-14-817Fig1.jpg
case_images: PMC5939903_02_tcrm-14-817Fig1.jpg
case_images: f1-tcrm-14-817
case_images: His lumbar and hip BMD values improved to 0.803 (10.3% increase) and 0.707 (3.2% increase), respectively, at 18 months afterward (Table 2 and Figure 1).
case_images: Percentage changes in BAP (A), urinary NTX (B), serum TRACP-5b (C), and active form of vitamin D or 1,25(OH)2D3 (D) before, and at 1, 4, 8, 12, 18, and 24 months after denosumab therapy.. Note: Patient 2 was followed up for 18 months, not 24 months.. Abbreviations: BAP, bone alkaline phosphatase; NTX, cross-linked N-terminal telopeptides of type I collagen; TRACP-5, tartrate-resistant acid phosphatase 5b; M, months.
case_images: tcrm-14-817Fig2.jpg
case_images: PMC5939903_01_tcrm-14-817Fig2.jpg
case_images: f2-tcrm-14-817
case_images: N-terminal telopep-tides of type I collagen (NTX), and serum tartrate-resistant acid phosphatase 5b (TRACP-5b) were suppressed during the treatment (Table 3 and Figure 2). No fractures occurred over the 2 years of denosumab treatment.
case_images: PMC5939903_02
case_images: Percentage changes in lumbar BMD (A) and total hip BMD (B) before, and at 6-8, 12, 18, and 24 months after denosumab therapy.. Note: Patient 2 was followed up for 18 months, not 24 months.. Abbreviations: BMD, bone mineral density; M, months.
case_images: tcrm-14-817Fig1.jpg
case_images: PMC5939903_02_tcrm-14-817Fig1.jpg
case_images: f1-tcrm-14-817
case_images: His lumbar and hip BMD values improved to 0.803 (10.3% increase) and 0.707 (3.2% increase), respectively, at 18 months afterward (Table 2 and Figure 1).